Publications by authors named "Hiddo J L Heerspink"

100Publications

SGLT2 inhibitors: expanding their Empire beyond diabetes.

Lancet Diabetes Endocrinol 2020 Dec 22. Epub 2020 Dec 22.

Diabetes Centre, Department of Internal Medicine, Amsterdam University Medical Centers, VUMC, 1081 HV Amsterdam, Netherlands.

View Article and Find Full Text PDF
December 2020

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice.

Kidney Int 2020 Dec 11. Epub 2020 Dec 11.

Department of Renal and Metabolic, The George Institute for Global Health, UNSW Sydney, Sydney, Australia; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands. Electronic address:

View Article and Find Full Text PDF
December 2020

Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease.

Circulation 2020 Nov 13. Epub 2020 Nov 13.

The George Institute for Global Health, Sydney, Australia; Department Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.

View Article and Find Full Text PDF
November 2020

Characterization and implications of the initial estimated glomerular filtration rate 'dip' upon sodium-glucose co-transporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial.

Kidney Int 2020 Nov 9. Epub 2020 Nov 9.

Department of Internal Medicine I, University Hospital Würzburg, Würzburg, Germany; Boehringer Ingelheim International GmbH, Ingelheim, Germany; Department of Diabetes, Central Clinical School, Monash University, Melbourne, Australia.

View Article and Find Full Text PDF
November 2020

New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction.

Kidney Int 2020 Nov 2. Epub 2020 Nov 2.

Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

View Article and Find Full Text PDF
November 2020

Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea).

Diabetes Obes Metab 2021 Feb 24;23(2):455-466. Epub 2020 Nov 24.

Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, The Catholic University of Korea, Seoul, Republic of Korea.

View Article and Find Full Text PDF
February 2021

Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial.

Lancet Diabetes Endocrinol 2020 11;8(11):903-914

Renal and Metabolic Division, The George Institute for Global Health, UNSW Sydney, Sydney, NSW, Australia; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands. Electronic address:

View Article and Find Full Text PDF
November 2020

An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials.

Int J Cardiol 2020 Sep 24. Epub 2020 Sep 24.

The George Institute for Global Health, UNSW Sydney, Sydney, Australia; Department of Cardiology, Royal Prince Alfred Hospital, Sydney, Australia; Sydney Medical School, University of Sydney, Australia; University of New South Wales, Sydney, Australia. Electronic address:

View Article and Find Full Text PDF
September 2020

Dapagliflozin in Patients with Chronic Kidney Disease.

N Engl J Med 2020 10 24;383(15):1436-1446. Epub 2020 Sep 24.

From the Department Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (H.J.L.H.); the George Institute for Global Health, Sydney (H.J.L.H., D.C.W.); Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden (B.V.S., M.L., C.D.S., A.-M.L.); the National Medical Science and Nutrition Institute Salvador Zubirán, Mexico City (R.C.-R.); the Departments of Medicine and Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA (G.M.C.); the Study Design and Biostatistics Center, University of Utah Health Sciences, Salt Lake City (T.G.); the Division of Nephrology, Nanfang Hospital, Southern Medical University, National Clinical Research Center for Kidney Disease, Guangzhou, China (F.-F.H.); KfH Kidney Center, Munich, and Department of Medicine 4, University of Erlangen-Nuremberg, Erlangen - both in Germany (J.F.E.M.); the Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow (J.J.V.M.), and the Department of Renal Medicine, University College London, London (D.C.W.) - both in the United Kingdom; Steno Diabetes Center Copenhagen, Gentofte, and the Department of Clinical Medicine, University of Copenhagen, Copenhagen - both in Denmark (P.R.); and the Department of Internal Medicine, UT Southwestern Medical Center, Dallas (R.D.T.).

View Article and Find Full Text PDF
October 2020

Correction of anemia by dapagliflozin in patients with type 2 diabetes.

J Diabetes Complications 2020 Dec 5;34(12):107729. Epub 2020 Sep 5.

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. Electronic address:

View Article and Find Full Text PDF
December 2020

[F]FDG Uptake in Adipose Tissue Is Not Related to Inflammation in Type 2 Diabetes Mellitus.

Mol Imaging Biol 2021 Feb 4;23(1):117-126. Epub 2020 Sep 4.

Department of Vascular Medicine, University of Groningen, University Medical Center Groningen, HP AA41, Hanzeplein 1, 9700RB, Groningen, The Netherlands.

View Article and Find Full Text PDF
February 2021

Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program.

J Am Soc Nephrol 2020 Oct 21;31(10):2446-2456. Epub 2020 Jul 21.

Department of Renal and Metabolic, The George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia

View Article and Find Full Text PDF
October 2020

Simple, fast and robust LC-MS/MS method for the simultaneous quantification of canagliflozin, dapagliflozin and empagliflozin in human plasma and urine.

J Chromatogr B Analyt Technol Biomed Life Sci 2020 Sep 26;1152:122257. Epub 2020 Jun 26.

University of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, Netherlands; University of Groningen, Groningen Research Institute of Pharmacy, Department of Pharmaceutical Analysis, Groningen, Netherlands.

View Article and Find Full Text PDF
September 2020

Renal outcomes of SGLT2 inhibitors and GLP1 agonists in clinical practice.

Nat Rev Nephrol 2020 08;16(8):433-434

Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, Netherlands.

View Article and Find Full Text PDF
August 2020

Mediators of the effects of canagliflozin on kidney protection in patients with type 2 diabetes.

Kidney Int 2020 09 27;98(3):769-777. Epub 2020 May 27.

The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia; University of New South Wales, Sydney, Australia; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center, Groningen, The Netherlands. Electronic address:

View Article and Find Full Text PDF
September 2020

Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes.

Transl Res 2020 08 11;222:17-27. Epub 2020 May 11.

University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. Electronic address:

View Article and Find Full Text PDF
August 2020

Exposure-response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials.

Br J Clin Pharmacol 2020 Nov 10;86(11):2192-2203. Epub 2020 May 10.

Department Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

View Article and Find Full Text PDF
November 2020

Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy.

Nephrol Dial Transplant 2020 03;35(Suppl 2):ii38-ii42

Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, The Netherlands.

View Article and Find Full Text PDF
March 2020

A metabolomics-based molecular pathway analysis of how the sodium-glucose co-transporter-2 inhibitor dapagliflozin may slow kidney function decline in patients with diabetes.

Diabetes Obes Metab 2020 07 25;22(7):1157-1166. Epub 2020 Mar 25.

Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

View Article and Find Full Text PDF
July 2020

Editorial: The role of sodium-glucose cotransporter 2 inhibitors in the management of chronic kidney disease.

Nephrol Dial Transplant 2020 01;35(Suppl 1):i1-i2

Department of Medicine, Division of Nephrology, University Hospital Würzburg, Würzburg, Germany.

View Article and Find Full Text PDF
January 2020

Exposure-response relationships for the sodium-glucose co-transporter-2 inhibitor dapagliflozin with regard to renal risk markers.

Diabetes Obes Metab 2020 06 17;22(6):916-921. Epub 2020 Feb 17.

Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

View Article and Find Full Text PDF
June 2020

Atrasentan in patients with diabetes and chronic kidney disease - Authors' reply.

Lancet 2020 01;395(10220):270

Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen 9700 RB, Netherlands.

View Article and Find Full Text PDF
January 2020

Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes.

JACC Heart Fail 2020 01 29;8(1):57-66. Epub 2019 Oct 29.

George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia; Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia; Imperial College London, London, United Kingdom. Electronic address:

View Article and Find Full Text PDF
January 2020

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.

Lancet Diabetes Endocrinol 2019 11 5;7(11):845-854. Epub 2019 Sep 5.

The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia; Concord Repatriation and General Hospital, Sydney, NSW, Australia. Electronic address:

View Article and Find Full Text PDF
November 2019

Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial.

Diabetes Obes Metab 2020 01 1;22(1):30-38. Epub 2019 Oct 1.

Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

View Article and Find Full Text PDF
January 2020

When drug treatments bias genetic studies: Mediation and interaction.

PLoS One 2019 28;14(8):e0221209. Epub 2019 Aug 28.

Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.

View Article and Find Full Text PDF
March 2020

Change in albuminuria as a surrogate endpoint.

Curr Opin Nephrol Hypertens 2019 11;28(6):519-526

Department of Clinical Pharmacy and Pharmacology.

View Article and Find Full Text PDF
November 2019

Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin.

Diabetes Obes Metab 2019 12 30;21(12):2635-2642. Epub 2019 Sep 30.

Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

View Article and Find Full Text PDF
December 2019

Effects of the sodium-glucose co-transporter-2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes.

Diabetes Obes Metab 2019 12 17;21(12):2667-2673. Epub 2019 Sep 17.

Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.

View Article and Find Full Text PDF
December 2019

The incretin pathway as a therapeutic target in diabetic kidney disease: a clinical focus on GLP-1 receptor agonists.

Ther Adv Endocrinol Metab 2019 24;10:2042018819865398. Epub 2019 Jul 24.

Amsterdam University Medical Centers, VUMC, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.

View Article and Find Full Text PDF
July 2019

Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes.

Diabetes Obes Metab 2019 11 18;21(11):2422-2428. Epub 2019 Jul 18.

Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, Groningen, The Netherlands.

View Article and Find Full Text PDF
November 2019

No significant association of type 2 diabetes-related genetic risk scores with glycated haemoglobin levels after initiating metformin or sulphonylurea derivatives.

Diabetes Obes Metab 2019 10 24;21(10):2267-2273. Epub 2019 Jun 24.

Groningen Research Institute of Pharmacy, PharmacoTherapy, Epidemiology and Economics, University of Groningen, Groningen, The Netherlands.

View Article and Find Full Text PDF
October 2019

Predicting individual treatment response in diabetes.

Lancet Diabetes Endocrinol 2019 06 29;7(6):415-417. Epub 2019 Apr 29.

Department of Clinical Pharmacy and Pharmacology, University of Groningen, 9700 AD Groningen, Netherlands. Electronic address:

View Article and Find Full Text PDF
June 2019

Prediction of the effect of dapagliflozin on kidney and heart failure outcomes based on short-term changes in multiple risk markers.

Nephrol Dial Transplant 2020 09;35(9):1570-1576

Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

View Article and Find Full Text PDF
September 2020

Change in albuminuria as a surrogate endpoint in chronic kidney disease - Authors' reply.

Lancet Diabetes Endocrinol 2019 05;7(5):336-337

Division of Nephrology, Tufts Medical Center, Boston, MA 02111, USA. Electronic address:

View Article and Find Full Text PDF
May 2019

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.

Diabetologia 2019 07 17;62(7):1154-1166. Epub 2019 Apr 17.

Department of Internal Medicine IV (Nephrology and Hypertension), Medical University of Innsbruck, Innsbruck, Austria.

View Article and Find Full Text PDF
July 2019

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

N Engl J Med 2019 06 14;380(24):2295-2306. Epub 2019 Apr 14.

From the George Institute for Global Health, University of New South Wales Sydney (V.P., M.J.J., B.N., S. Bompoint), the Royal North Shore Hospital (V.P.), Concord Repatriation General Hospital (M.J.J.), and the Charles Perkins Centre, University of Sydney (B.N.), Sydney, and the Kolling Institute of Medical Research, Sydney Medical School, University of Sydney, Royal North Shore Hospital, St. Leonards, NSW (C.P.) - all in Australia; Imperial College London (B.N.) and the Department of Renal Medicine, UCL Medical School (D.C.W.) - both in London; the Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (H.J.L.H., D.Z.); the Nephrology Division, NYU School of Medicine and NYU Langone Medical Center, New York (D.M.C.); Baim Institute for Clinical Research (D.M.C., C.P.C., B.M.B.), the Cardiovascular Division (C.P.C.) and the Renal Division and Department of Medicine (B.M.B), Brigham and Women's Hospital, and Harvard Medical School (B.M.B.) - all in Boston; Janssen Research and Development, Raritan, NJ (R.E., S. Bull, G.C., P.-L.C., Y.Y., G.M.); Indiana University School of Medicine and Veterans Affairs Medical Center, Indianapolis (R.A.); the Department of Medicine, University of Chicago Medicine, Chicago (G.B.); the Division of Biostatistics, Department of Population Health Sciences, University of Utah, Salt Lake City (T.G.); the Division of Nephrology, University of British Columbia, Vancouver (A.L.), and the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto (B.Z.) - all in Canada; the Renal Division, Peking University First Hospital, Beijing (H.Z.); and the Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA (K.W.M.).

View Article and Find Full Text PDF
June 2019

Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus.

Curr Opin Nephrol Hypertens 2019 07;28(4):321-327

Division of Nephrology, Department of Internal Medicine.

View Article and Find Full Text PDF
July 2019

Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney.

Nephrol Dial Transplant 2019 12;34(12):2015-2017

Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands.

View Article and Find Full Text PDF
December 2019

Multimarker Panels in Diabetic Kidney Disease: The Way to Improved Clinical Trial Design and Clinical Practice?

Kidney Int Rep 2019 Feb 18;4(2):212-221. Epub 2018 Dec 18.

Department of Internal Medicine IV (Nephrology and Hypertension), Medical University Innsbruck, Innsbruck, Austria.

View Article and Find Full Text PDF
February 2019

New pharmacological strategies for protecting kidney function in type 2 diabetes.

Lancet Diabetes Endocrinol 2019 05 19;7(5):397-412. Epub 2018 Dec 19.

Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands.

View Article and Find Full Text PDF
May 2019

ACCORDION: Ensuring That We Hear the Music Clearly.

Clin J Am Soc Nephrol 2018 11 25;13(11):1621-1623. Epub 2018 Oct 25.

Division of Renal and Metabolic, The George Institute for Global Health, University of New South Wales, Sydney, Australia;

View Article and Find Full Text PDF
November 2018

New clinical trial designs for establishing drug efficacy and safety in a precision medicine era.

Diabetes Obes Metab 2018 10;20 Suppl 3:14-18

George Institute for Global Health, UNSW Sydney, Sydney, NSW, Australia.

View Article and Find Full Text PDF
October 2018

Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations.

Diabetes Obes Metab 2018 10;20 Suppl 3:19-23

Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.

View Article and Find Full Text PDF
October 2018